Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland : applying a coherent framework to drug utilisation studies by Mueller, Tanja et al.
Mueller, Tanja and Alvarez-Madrazo, Samantha and Robertson, Charles 
and Bennie, Marion (2017) Use of direct oral anticoagulants in patients 
with atrial fibrillation in Scotland : applying a coherent framework to 
drug utilisation studies. Pharmacoepidemiology and Drug Safety. ISSN 
1053-8569 , http://dx.doi.org/10.1002/pds.4272
This version is available at https://strathprints.strath.ac.uk/61229/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
OR I G I N A L R E POR T
Use of direct oral anticoagulants in patients with atrial
fibrillation in Scotland: Applying a coherent framework to drug
utilisation studies
Tanja Mueller1 | Samantha Alvarez‐Madrazo1 | Chris Robertson2 | Marion Bennie1,3
1Strathclyde Institute of Pharmacy and
Biomedical Sciences, University of Strathclyde,
Glasgow, UK
2Department of Mathematics and Statistics,
University of Strathclyde, Glasgow, UK
3Public Health and Intelligence Strategic
Business Unit, NHS National Services
Scotland, Edinburgh, UK
Correspondence
M. Bennie, Strathclyde Institute of Pharmacy
and Biomedical Sciences, Robertson Trust
Wing, University of Strathclyde, 40 Taylor
Street, Glasgow, UK.
Email: marion.bennie@strath.ac.uk
Funding information
Farr Institute; MRC, Grant/Award Number:
MR/K007017/1
Abstract
Purpose: To report the use of direct oral anticoagulants (DOACs) for stroke prevention in
patients with atrial fibrillation in Scotland and advocate the standardisation of drug utilisation
research methods.
Methods: Retrospective cohort study using linked administrative data. Patients included
those with a diagnosis of atrial fibrillation (confirmed in hospital) who received a first prescription
for a DOAC (dabigatran, rivaroxaban, or apixaban) from September 2011 to June 2014. Drug
utilisation measures included discontinuation, persistence, and adherence.
Results: A total of 5398 patients (mean CHA2DS2‐VASc score 2.98 [SD 1.71], 89.7% with ≥5
concomitant medicines) were treated with DOACs for a median of 228 days (interquartile range
105‐425). Of 35.6% who discontinued DOAC treatment, 11.0% switched to warfarin, and 48.3%
reinitiated DOACs. Persistence after 12 and 18 months was 75.9% and 69.8%, respectively. Dif-
ferences between individual DOACs were observed: Discontinuation rates ranged from 20.4%
(apixaban) to 60.6% (dabigatran) and 12 months persistence from 60.1% (dabigatran) to 85.5%
(apixaban). Adherence to treatment with all DOACs was good: Overall DOAC median medication
refill adherence was 102.9% (interquartile range 88.9%‐115.5%), and 82.3% of patients had a
medication refill adherence > 80%.
Conclusions: In Scotland, adherence to DOAC treatment was good, and switching from
DOAC to warfarin was low. However, discontinuation and persistence rates were variable—
although treatment interruptions were often temporary.
To decrease the inconsistencies in drug utilisation methods and facilitate meaningful study com-
parison, the use of a coherent framework—using a combination of discontinuation, persistence,
and adherence—and the standardisation of measurements is advocated.
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1 | INTRODUCTION
Drug utilisation research (DUR) is frequently conducted to analyse the
use of drugs, and a core aspect is adherence to drug treatment, defined
as the extent to which patients take drugs according to prescribing
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instructions.1 Nonadherence to drugs is widespread1-3 and has been
linked to increases in morbidity, premature death, and health care
expenditure;1,4,5 especially nonadherence to drugs with complex phar-
macological profiles such as warfarin and other vitamin K antagonists
(VKAs) is known to negatively affect treatment outcomes.6-9
Warfarin is used for multiple cardiovascular conditions, and high dis-
continuation rates of warfarin treatment have been reported in clinical tri-
als and observational studies;10-12 poor adherence has been ascribed to a
variety of issues, from the occurrence of bleeding events to the inconve-
nience of treatment.6,13-15Aswarfarin is widely used long‐term in patients
with atrial fibrillation (AF)—a common condition causing irregular heart-
beat and, as such, a major independent risk factor for stroke16,17—efforts
to replace warfarin have resulted in 4 new direct oral anticoagulants
(DOACs) being introduced since 2008: dabigatran, a direct thrombin inhib-
itor, and rivaroxaban, apixaban, and edoxaban, direct factor Xa inhibitors.
Treatment with DOACs follows easier dosing schemes and theoreti-
cally requires no monitoring, primarily because their therapeutic windows
are wider and interactions with other drugs/foods are shown to be less
than with warfarin.18,19 Treatment with DOACs is deemed as effective
and safe as with warfarin;20-23 the effect of nonadherence on bleeding
risk and stroke incidence among AF patients has been addressed but as
yet not intensely studied.24,25 Recently, concerns have been raised about
the potential impact of nomonitoring and the presence of multimorbidity
and polypharmacy on DOAC adherence.24,26-29 Knowledge about
patients' adherence toDOACs in real life is however still limited, and stud-
ies conducted thus far differ in scale, methodology, and focus.25,30-41
Results emerging from DUR studies are frequently used to com-
pare uptake and use of drugs over time and between regions. Addition-
ally, information on treatment adherence can be used to improve the
accuracy of drug exposure estimates when investigating treatment
outcomes in clinical practice—as compared to clinical trials results.42
Nevertheless, although a comprehensive framework of drug adher-
ence and a common terminology for measuring adherence have been
proposed by the European Society for Patient Adherence, Compliance
and Persistence,43DUR studies still make use of a variety of definitions
and measurements, with methods of calculation also differing.44-46 The
objective of this study is therefore 2‐fold: first, to report on the use of
DOACs for stroke prevention in patients with AF identified in Scottish
secondary care; and second, to advocate the standardisation of DUR
by applying an evolving methods approach, based on a sound theoret-
ical framework and well‐documented measurements of adherence.
2 | METHODS
In Scotland (population approximating 5.3 million47), all residents are
covered by the publicly funded National Health Service (NHS), with
most clinical services including prescriptions provided free of charge
at the point of care.48
Prescription details have been derived from the Prescribing Information
System (PIS)—anNHSScotland national database created primarily for reim-
bursement purposes.49 The PIS holds data on the prescribed and dispensed
items, patients, and prescribers, including a range of drug‐specific informa-
tion based on the British National Formulary.49,50 Clinical data have been
extracted from the Scottish Morbidity Records/Hospital inpatients dataset
(SMR01), comprising diagnostic codes according to the International Classi-
fication of Diseases, 10th edition, and Office of Population Censuses and
Surveys procedural codes, 4th revision.51-53 PIS and SMR01 have been
linked using the Community Health Index, a unique patient identifier issued
to all residents registered with a general practitioner in Scotland.54
The study population comprises patientswith a diagnosis of AF, con-
firmed in secondary care between January 1997 and June 2014, who
received a DOAC between the date of a drug's approval for the indica-
tion of stroke prevention in patients with AF in Scotland (dabigatran:
September 2011; rivaroxaban: January 2012; and apixaban: January
2013) and June 2014. For details about inclusion and exclusion criteria,
see Appendix 1. A patient's index date for study inclusion was the date
of first recorded prescription for any DOAC; their individual end date
was either date of death or removal from a Scottish general practitioner
register for other reasons, or the study end date (June 30, 2014), which-
ever occurred first. To assess baseline characteristics of patients, all avail-
able hospital records 5 years prior to the index date have been used. A
time period of 6 months before the index date has been applied to define
concomitant medication. Dispensed quantities and prescription dates
have been used throughout the study.
Drug utilisation can be divided into 3 distinct parts: initiation,
implementation, and discontinuation.43,55 While initiation and discon-
tinuation indicate the start and end of a therapy, the process of imple-
mentation illustrates whether medication was taken as prescribed. To
give a valid representation of patients' drug taking behaviour and
enable analysis of drug exposure, duration and intensity of treatment
should be taken into account. Hence, this study includes measures of
both discontinuation/persistence and adherence. Discontinuation has
been calculated using the refill‐gap method with censoring of patients
after the first discontinuation event,56 defined as a gap of more than
28 days without supply following the assumed end of a prescription,
based on summary statistics of the data and comparable to previous
studies.30,35 In addition, a second discontinuation rate—allowing for
reinitiation of treatment during the study period—has been introduced
(cessation rate). In line with the literature, persistence at prespecified
points in time (6, 12, and 18 months after treatment initiation) has been
assessed using the anniversary method to account for intermediary
KEY POINTS
• Using Scottish national administrative data, we analysed
the utilisation of the direct oral anticoagulants (DOACs)
dabigatran, rivaroxaban, and apixaban in 5398 patients
with atrial fibrillation between September 2011 and
June 2014.
• Adherence to DOAC treatment was good, and switching
from DOAC to warfarin was low. However,
discontinuation and persistence rates were variable.
• Standardisation of drug utilisation studies using the
ESPACOM framework, combining measurements of
discontinuation, persistence, and adherence, is strongly
advocated.
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TABLE 1 Utilisation measurements as used in this study, definitions, and calculation methods
Measurement Definition Calculation
Discontinuation
rate56
Discontinuation rate (refill‐gap method) Patients discontinuing treatment
(ie, supply gap exceeding 28 days)
(Patients discontinuing treatment /
patients initiating treatment) * 100
Cessation rate (allowing for treatment
interruptions)
Patients ceasing treatment (ie, no
further prescription for any DOAC
during the study period)
(Patients ceasing treatment / patients
initiating treatment) * 100
Persistence
rate56
Persistence after 6, 12, and 18 months
(anniversary method)
Patients still on treatment 6, 12, and
18 months after initiation
(Patients with drug supply covering the
anniversary date / patients with
sufficient follow‐up time) * 100
Adherence45 Medication refill adherence (MRA) Exposure to medication covering
the time period of treatment
(Total days' supply / total days in
study) * 100
Compliance rate (CR) Exposure to medication covering
the time period of treatment
(Total days' supply—last refill) / days
first up to, but not including
last refill) * 100
Continuous, single‐interval measure
of medication availability (CSA)
Exposure to medication covering the
time period between individual
dispensations
(Days' supply per dispensing / days in
dispensing interval) * 100
TABLE 2 Patients' baseline characteristics, overall and by first drug prescribed
DOAC
(n = 5398)
Dabigatran
(n = 1016)
Rivaroxaban
(n = 3292)
Apixaban
(n = 1090)
Calendar year of first prescription (%)
2011 51 (0.9) 51 (5.0) 0 0
2012 911 (16.9) 411 (40.5) 500 (15.2) 0
2013 2426 (44.9) 405 (39.9) 1624 (49.3) 397 (36.4)
2014 2010 (37.2) 149 (14.7) 1168 (35.5) 693 (63.6)
Female (%) 2472 (45.8) 400 (39.4) 1548 (47.0) 524 (48.1)
Mean age first prescription (SD) 74.4 (11.3) 71.6 (11.8) 75.3 (10.9) 74.3 (11.5)
Patient age category at time of first prescription (%)
<50 169 (3.1) 44 (4.3) 80 (2.4) 45 (4.1)
50‐64 763 (14.1) 212 (20.9) 407 (12.4) 144 (13.2)
65‐74 1453 (26.9) 306 (30.1) 862 (26.2) 285 (26.1)
75‐84 2007 (37.2) 310 (30.5) 1279 (38.9) 418 (38.3)
85+ 1006 (18.6) 144 (14.2) 664 (20.2) 198 (18.2)
Co‐morbidities as included in CHA2DS2‐VASc score (%)
a
Congestive heart failure 1007 (18.7) 163 (16.0) 608 (18.5) 236 (21.7)
Hypertension 2067 (38.3) 379 (37.3) 1268 (38.5) 420 (38.5)
Diabetes mellitus 840 (15.6) 151 (14.9) 533 (16.2) 156 (14.3)
Prior stroke/TIA 839 (15.5) 144 (14.2) 520 (15.8) 175 (16.1)
Vascular disease 547 (10.1) 96 (9.4) 347 (10.5) 104 (9.5)
Mean CHA2DS2‐VASc score (SD) 2.98 (1.71) 2.65 (1.74) 3.07 (1.70) 3.03 (1.65)
Prior VKA use yes (%) 2595 (48.1) 479 (47.1) 1644 (49.9) 472 (43.3)
Concomitant antiplatelet use (%)b 599 (11.1) 91 (9.0) 364 (11.1) 144 (13.2)
Concomitant aspirin use (%)c 1846 (34.2) 411 (40.5) 1039 (31.6) 396 (36.3)
Concomitant NSAID use (%)b 327 (6.1) 80 (7.9) 176 (5.3) 71 (6.5)
Concomitant use of contraindicated drugs (%)d 118 (2.2) 9 (0.9) 78 (2.4) 31 (2.8)
Concomitant use of drugs that should be avoided (%)e 268 (5.0) 53 (5.2) 147 (4.5) 68 (6.2)
Mean number different drugs prior to DOAC initiation (SD) 10.8 (5.5) 9.8 (5.2) 11.0 (5.5) 11.0 (5.5)
Abbreviations: DOAC, direct oral anticoagulant; NSAID, non‐steroidal anti‐inflammatory drug; SD, standard deviation; TIA, transient ischaemic attack; VKA,
vitamin K antagonist.
aBased on hospital records only—ICD‐10 codes included in the CHA2DS2‐VASc score can be found in Appendix 2.
bExcluding aspirin.
cIncludes only prescribed aspirin—potential underestimation of use as aspirin can be acquired over‐the‐counter in Scotland.
dDabigatran: itraconazole, ketoconazole; rivaroxaban and apixaban: carbamazepine, itraconazole, ketoconazole, phenytoin, rifampicin.50
eDabigatran: carbamazepine, clarithromycin, phenytoin; rivaroxaban and apixaban: clarithromycin.50
MUELLER ET AL. 3
treatment interruptions.56 As no “gold standard” to quantify adherence
has been agreed upon, triangulation of measurements selected based
on a literature review has been applied. See Table 1 for details. Drug
utilisation measures are rations and are summarised using medians
and interquartile ranges (IQRs).
Kaplan‐Meier survival analysis has been used to calculate median
time to discontinuation; follow‐up has been censored after 1 year for
apixaban and after 2 years for dabigatran and rivaroxaban. Events have
been coded as 1 = treatment discontinuation and 0 = still on treatment
at end of follow‐up. All data analyses have been conducted using the R
software, version 3.3.1.57
Because of the nature of the study, ethical approval was not
required; however, use of the data has been approved by the appropri-
ate Privacy Advisory Committee. The data were hosted and managed
by the NHS Scotland National Safe Haven.
3 | RESULTS
A total of 5398 patients were included in the study, 48.1% of whom
used a VKA in the 6‐month period preceding DOAC treatment. Overall
median follow‐up time was 228 days (IQR 105‐425), ranging from
124.5 days (IQR 54‐226.2) for apixaban to 467 days (IQR
237.8‐719.2) for dabigatran. The median number of DOAC prescrip-
tions issued to patients was 5 (IQR 2‐9); 15.6% of patients received
only one DOAC prescription.
Multimorbidity and polypharmacy were widespread. Most
patients (89.7%) were treated with 5 or more different drugs concom-
itantly; most prevalent medications were beta‐blockers (66.5% of
patients), statins (57.1%), drugs influencing the renin‐angiotensin sys-
tem (55.4%), diuretics (51.9%), and analgesics other than non‐steroidal
anti‐inflammatory drugs (50.3%). Prior to treatment initiation, drugs
that should either be avoided or are contraindicated in combination
with DOACs were prescribed to 5.0% and 2.2% of patients, respec-
tively. Table 2 gives an overview of patients' baseline characteristics
by first DOAC prescribed.
When looking at DOACs in general—ie, disregarding switches
between individual drugs—1923 patients (35.6%) discontinued treat-
ment during the study period, and the median time to discontinuation
was 393 days (95% CI, 374‐428 days); however, 48.3% of patients
discontinuing reinitiated treatment with any DOAC at least temporar-
ily (see Figure 1 for details). By study conclusion, 1186 patients had
stopped receiving DOAC prescriptions, resulting in a cessation rate
of 22.0%; this figure includes patients ceasing all oral anticoagulant
treatment as well as those switching lastingly to a VKA.
For individual DOACs, a total of 1995 patients (37.0%)
discontinued treatment with the first drug prescribed, and discontinu-
ation rates differed substantially between drugs: 20.4% apixaban,
35.1% rivaroxaban, and 60.6% dabigatran. Median time to
discontinuation was considerably shorter for dabigatran (206 days;
95% CI, 185‐247 days) than rivaroxaban (414 days; 95% CI,
382‐462). While 35.1% of apixaban patients who discontinued
restarted treatment, proportions for dabigatran and rivaroxaban
were 44.2% and 46.1%, respectively; accounting for reinitiations,
the share of patients who eventually ceased treatment with their
index drug ranged from 14.4% for apixaban to 42.4% for
dabigatran. Survival curves of patients discontinuing treatment,
regardless of permanency, in contrast to patients ceasing treatment,
are shown in Figure 2.
Crude persistence with DOAC treatment regardless of switches
between individual drugs was 82.1%, 75.9%, and 69.8% at 6, 12 and
18 months, respectively. Persistence for individual drugs at 6, 12, and
18 months was 68.9%, 60.1%, and 54.7% for dabigatran and 83.5%,
79.0%, and 74.9% for rivaroxaban. Persistence with apixaban was
86.8% at 6 months and 85.5% at 12 months; insufficient data were
available at 18 months.
FIGURE 1 Patients' treatment options after
DOAC discontinuation. DOAC, direct oral
anticoagulant; VKA, vitamin K antagonist
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Extending the length of admissible gap without drug supply
from 28 to 56 days considerably decreased the DOAC discontinua-
tion rate to 20.0%, but had less of an impact on persistence rates;
persistence increased at 6 months to 85.8% and at 12 months to
77.9%. Relative differences between individual DOACs were not
affected. Additional results of the sensitivity analysis can be found
in Appendix 3.
A total of 4555 patients (84.4%) received at least 2 DOAC pre-
scriptions and have been included in calculations of adherence to
treatment. All adherence measurements gave comparable results and
indicate high adherence to DOAC treatment, albeit with differences
between individual drugs. Adherence remained stable over time when
looking at 6 months intervals rather than assessing patients' entire
treatment periods; see Table 3 for details.
4 | DISCUSSION
This is the first study in Scotland using linked data from PIS and
SMR01 to analyse discontinuation, persistence, and adherence to
DOAC treatment and one of a small number of studies analysing rou-
tinely collected data at a national level.25,33 Additionally, it is one of the
first studies to apply the European Society for Patient Adherence,
Compliance and Persistence framework for drug utilisation studies43
in combination with proposed standardised measurements for drug
adherence;45 it encompasses all dimensions of drug utilisation rather
than focusing on a single aspect and therefore gives a much more com-
prehensive picture of how DOACs are used in clinical practice than
previous studies.
Our findings are, at large, comparable to other research: AF
patients being treated with DOACs are in general elderly, have high
levels of co‐morbidities, and receive a large number of additional
drugs;31,32,34,38,58 discontinuation of treatment varies considerably
between individual DOACs;30,32,38,40 and persistence declines over
time.32,35 Nevertheless, two important differences need to be
highlighted: First, adherence to treatment was considerably higher
in our study than has been reported in other studies conducted on
a national level;25,33 and second, switches from DOACs to VKAs
were much less common than in previous observational
studies.31,36,38
The crude discontinuation rate and 12 months persistence to
DOAC treatment in Scotland were 35.6% and 75.9%, respectively,
and similar rates have been reported before;35,41 however, most stud-
ies reporting on discontinuation and/or persistence either did not
explicitly describe how rates have been calculated or did not clearly
distinguish between the different concepts of discontinuation and per-
sistence. In our study, 48.3% of patients discontinuing treatment sub-
sequently received at least one additional prescription for any DOAC,
ie, eventually resumed treatment. When allowing for treatment inter-
ruptions by using only the number of patients where no subsequent
DOAC prescriptions were recorded—a figure considerably influenced
by length of follow‐up, as more patients might reinitiate treatment
over time—the crude DOAC discontinuation rate was 22.0%, highlight-
ing that the method of calculation where patients are censored after
the occurrence of a first discontinuation event likely leads to an over-
estimation of discontinuation. This lower discontinuation rate is also
more in agreement with the persistence rates found in this study, cal-
culated using the anniversary method that is insensitive to periods of
treatment interruptions.56
The percentage of patients switching from a DOAC to VKA treat-
ment was low in this study (11.0%) compared to patients in Denmark
(51.2%) and Japan (54%), but higher than in England (6.0%), and similar
to the 1‐year follow‐up EORP‐AF pilot registry (11.8%);35,36,38,59 the
reasons for these diverse findings are unclear, but might be rooted
either in differences in clinical guidelines and physicians' preferences,
or in timing of studies and availability of DOACs.
Although many studies report on DOACs as a group rather than
separately by individual drugs, our results confirm previous findings
indicating sizable differences between individual drugs: Dabigatran
frequently exhibits discontinuation rates higher than rivaroxaban and
apixaban.32,38 Consequently, 12 months persistence has reportedly
FIGURE 2 Kaplan‐Meier survival curves by drug [Colour figure can be
viewed at wileyonlinelibrary.com]
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been lowest for dabigatran, ranging from 44.7% to 74.4% compared to
60.1% to 77.4% for rivaroxaban and up to 85.9% for apixaban32,34—
results that match our own findings of 60.1% (dabigatran), 79.0%
(rivaroxaban), and 85.5% (apixaban).
Discontinuation of DOAC treatment has often been attributed to
changes in underlying disease severity, including restoration of sinus
rhythm, worsening kidney function, and side effects including bleeding
events or, particularly in case of dabigatran, gastrointestinal distur-
bances.31,38,41 Because of the data available for this study, specific rea-
sons for treatment discontinuations among the study population
remain unknown.
Adherence to medication was high for all drugs and did not consid-
erably decline over time. Treatment gaps were rare, patients generally
having enough medication to cover the treatment period; median med-
ication refill adherence, and compliance rate during the first 6months of
treatment, indicated oversupply rather than undersupply of drugs,
although these findings might be due to the timing of prescriptions.
High median adherence to DOAC treatment has been shown before:
between 94% and 99.7%37,39 for dabigatran and up to 100% for
rivaroxaban and apixaban.30 Results differ however, whichmight in part
be due to distinct methodology, as calculation methods for adherence
and analysable time periods varied between studies. Moreover, results
are frequently reported in dichotomised form, with a threshold of 80%
of the calculated measurement used to identify adherent patients; find-
ings using this approach range from 38.5% to 92.0% for
dabigatran,25,33,34,37,39 50.5% to 96% for rivaroxaban,25,30,34 and
61.9% to 95% for apixaban25,30,34—placing our findings of the propor-
tion of patients with a compliance rate > 80% of 84.6%, 92.3%, and
91.4% for dabigatran, rivaroxaban, and apixaban, respectively, at the
upper end of each scale. Comparing our findings obtained with 3 differ-
ent adherencemeasurements, applied to the study data, illustrated how
differences in calculation methods can impact the results; these obser-
vations raise concerns regarding comparability and generalisability of
findings, especially when methods are not clearly described.
This study has a number of limitations. First, by identifying eligible
patients to be included in the study in secondary care, patients diag-
nosed and treated exclusively in primary care were not captured. A
recent study, conducted in England, identified that 42.1% of AF
patients had an initial diagnosis in primary care;60 however, as many
of these patients are relatively elderly, a proportion might subse-
quently be admitted to hospital, and therefore, the percentage of
patients potentially not included in our study is likely to be lower than
40%. We do not anticipate this having a large impact on our findings
regarding adherence, persistence, and discontinuation. Second, the
data used for analysis have not been collected for the specific purpose
of this study but were gathered routinely in daily care. Therefore, not
all desirable information was present; in particular, no indication for
why drugs have been prescribed has been available. This might have
resulted in the inclusion of patients who had AF but were treated with
DOACs for other reasons—specifically, treatment with any DOAC for
up to 6 months due to deep vein thrombosis—potentially leading to
imprecision in results due to diverging anticipated treatment lengths
and dosing schedules. In Figure 2, there is a small drop at 180 days
of only about 3%, so the impact of this on persistence is likely to be
small. Dose instructions as recorded by the prescriber have been used
supplementary to drug supply based on standard dosing guidelines to
TABLE 3 Adherence to treatment, overall and by first drug prescribed
DOAC (n = 4555) Dabigatran (n = 864) Rivaroxaban (n = 2821) Apixaban (n = 822)
MRA > 80% (%)a 82.3 64.5 83.3 88.0
Median MRA (IQR)a 102.9 (88.9‐115.5) 95.1 (56.7‐107.1) 103.1 (90.3‐115.0) 107.2 (93.5‐124.7)
Median MRA over time (IQR)b
0‐6 months 108.9 (93.3‐124.4) 100.0 (83.3‐116.7) 108.9 (93.3‐124.4) 111.7 (93.3‐124.4)
7‐12 months 112.0 (100.6‐125.4) 110.6 (98.6‐124.2) 111.5 (101.2‐125.3) 111.7 (98.8‐123.5)
13‐18 months 112.0 (101.2‐126.4) 112.0 (98.9‐125.9) 112.0 (103.1‐126.3) n/a
CR > 80% (%)a 90.6 84.6 92.3 91.4
Median CR (IQR)a 103.5 (95.1‐115.3) 100.6 (90.7‐110.0) 103.7 (96.2‐115.9) 104.7 (96.0‐121.4)
Median CR over time (IQR)b
0‐6 months 105.3 (96.0‐117.2) 103.5 (92.0‐115.4) 105.7 (96.6‐117.5) 104.2 (96.0‐115.5)
7‐12 months 100.0 (94.1‐108.4) 100.7 (92.3‐109.4) 100.0 (94.1‐107.7) 100.0 (96.1‐107.1)
13‐18 months 100.8 (94.0‐108.5) 101.4 (90.9‐110.1) 100.6 (95.2‐108.4) n/a
Median CSA (IQR)a 100.0 (90.3‐122.4) 100.0 (87.0‐120.0) 100.0 (90.3‐124.4) 103.4 (88.9‐130.4)
Median CSA over time (IQR)b
0‐6 months 103.7 (90.3‐133.3) 103.4 (88.2‐130.4) 103.7 (90.3‐133.3) 103.7 (90.3‐133.3)
7‐12 months 100.0 (90.3‐116.7) 101.7 (88.2‐120.0) 100.0 (90.3‐116.7) 100.0 (88.7‐112.0)
13‐18 months 100.0 (90.3‐116.7) 100.0 (88.2‐117.6) 100.0 (90.3‐116.7) n/a
Abbreviations: CR, compliance rate; CSA, continuous, single‐interval measure of medication availability; DOAC, direct oral anticoagulant; IQR, interquartile
range; MRA, medication refill adherence.
To calculate adherence, only patients who received at least 2 prescriptions have been included. Discrepancies between the total number of patients receiv-
ing 2 prescriptions for any DOAC (n = 4555) and the sum of patients receiving at least 2 prescriptions for dabigatran, rivaroxaban, or apixaban (n = 4507) are
due to patients switching drugs after only one prescription for an initial drug.
aIncludes all patients with at least 2 prescriptions during the study period.
bIncludes only patients with sufficient follow‐up time to cover the respective prescription period.
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limit the impact of variations in dosing schedules on adherence. Finally,
as prescription records do not cover secondary care, in‐patient periods
are not included; this might have impacted adherence and persistence,
as hospital days could have appeared to be treatment interruptions.
Sensitivity analysis of the lengths of admissible gaps and the additional
measurement of treatment cessation have been used to account for
the potential effect of in‐patient episodes on discontinuation and
persistence.
This study has nevertheless several strengths: Access to health
care is universal, and electronic health records in Scotland cover the
entire population. Because of the presence of a unique patient identi-
fier, records can easily and reliably be linked; a large variety of variables
is therefore available, including those essential for calculating adher-
ence to medication. Furthermore, PIS and SMR01 have previously
been used for research, and validity and accuracy of the data has been
established.49,52
5 | CONCLUSION
In Scotland, adherence to DOAC treatment was high, and switching from
DOAC to warfarin was low. However, discontinuation and persistence
rates were variable—although treatment interruptions were often tem-
porary. The effects of nonadherence, including treatment interruptions,
on the safety and effectiveness of DOACs need to be investigated fur-
ther; more research is needed to analysewhether treatmentwith DOACs
does indeed result in better disease outcomes as compared to warfarin.
To decrease the inconsistencies in drug utilisation methodology
impacting the comparability of results across studies, the use of a
coherent framework—using a combination of discontinuation, persis-
tence, and adherence—and the standardisation of measurements is
strongly advocated.
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